97 related articles for article (PubMed ID: 8483556)
1. Mitomycin: its evolving role in the treatment of breast cancer.
Hortobagyi GN
Oncology; 1993 Apr; 50 Suppl 1():1-8. PubMed ID: 8483556
[TBL] [Abstract][Full Text] [Related]
2. Mitoxantrone, mitomycin-C, methotrexate combination chemotherapy with radiotherapy and/or surgery in stage III (T4B, NO-2, M0) breast cancer.
Raina V; Sharma A; Deo SV; Shukla NK; Mohanty BK; Goel A; Rath GK
J Assoc Physicians India; 1998 Nov; 46(11):926-9. PubMed ID: 11229215
[TBL] [Abstract][Full Text] [Related]
3. A review of mitomycin regimens in advanced breast cancer therapy.
Legha SS
Clin Ther; 1985; 7(3):286-307. PubMed ID: 3888391
[TBL] [Abstract][Full Text] [Related]
4. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel with mitoxantrone with or without 5-fluorouracil and high-dose leucovorin in the treatment of metastatic breast cancer.
Greco FA; Hainsworth JD
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-61-S17-64. PubMed ID: 9374096
[TBL] [Abstract][Full Text] [Related]
6. Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes.
Tanabe M; Ito Y; Tokudome N; Sugihara T; Miura H; Takahashi S; Seto Y; Iwase T; Hatake K
Breast Cancer; 2009; 16(4):301-6. PubMed ID: 19205831
[TBL] [Abstract][Full Text] [Related]
7. Salvage therapy for metastatic disease.
Sedlacek SM
Semin Oncol; 1990 Aug; 17(4 Suppl 7):45-9. PubMed ID: 2200132
[TBL] [Abstract][Full Text] [Related]
8. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer.
Elias AD; Richardson P; Avigan D; Ibrahim J; Joyce R; Demetri G; Levine J; Warren D; Arthur T; Reich E; Wheele C; Frei E; Ayash L
Bone Marrow Transplant; 2001 Feb; 27(3):269-78. PubMed ID: 11277174
[TBL] [Abstract][Full Text] [Related]
9. [Chemo-endocrine therapy including mitomycin C and medroxyprogesterone acetate in doxorubicin-refractory advanced breast cancer].
Nomura Y; Tashiro H; Shirouzu M; Takayama T
Gan To Kagaku Ryoho; 1996 Mar; 23(4):439-45. PubMed ID: 8678495
[TBL] [Abstract][Full Text] [Related]
10. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
[TBL] [Abstract][Full Text] [Related]
11. Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642).
Costanza ME; Berry D; Henderson IC; Ratain MJ; Wu K; Shapiro C; Duggan D; Kalra J; Berkowitz I; Lyss AP
Clin Cancer Res; 1995 Jul; 1(7):699-704. PubMed ID: 9816035
[TBL] [Abstract][Full Text] [Related]
12. Mitomycin C, methotrexate, and vincristine with medroxyprogesterone acetate or prednisolone for doxorubicin resistant advanced breast cancer--a randomized control study.
Tashiro H; Nomura Y
Anticancer Res; 1995; 15(5B):2229-37. PubMed ID: 8572630
[TBL] [Abstract][Full Text] [Related]
13. [Simultaneous radiochemotherapy in recurrent and metastatic breast neoplasm. Clinical experience].
Plasswilm L; Sauer R
Strahlenther Onkol; 1995 Dec; 171(12):689-93. PubMed ID: 8545790
[TBL] [Abstract][Full Text] [Related]
14. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
15. Carboplatin in combination therapy for metastatic breast cancer.
Perez EA
Oncologist; 2004; 9(5):518-27. PubMed ID: 15477636
[TBL] [Abstract][Full Text] [Related]
16. [CMF or CAF combination chemotherapy for breast cancer].
Ota J
Gan To Kagaku Ryoho; 1996 Dec; 23(14):1886-90. PubMed ID: 8978791
[TBL] [Abstract][Full Text] [Related]
17. Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience.
Hudis C; Seidman A; Raptis G; Fennelly D; Gilewski T; Baselga J; Theodoulou M; Sklarin N; Moynahan M; Surbone A; Currie V; Lebwohl D; Uhlenhopp M; Crown J; Norton L
Semin Oncol; 1996 Feb; 23(1 Suppl 1):58-64. PubMed ID: 8629040
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer.
D'Andrea G; Fennelly D; Norton L; Baselga J; Gilewski T; Hudis C; Moynahan ME; Raptis G; Sklarin N; Surbone A; Theodoulou M; Templeton MA; Yao TJ; Seidman AD
Clin Cancer Res; 1999 Feb; 5(2):275-9. PubMed ID: 10037175
[TBL] [Abstract][Full Text] [Related]
19. Experience with mitomycin in the treatment of non-small cell lung cancer.
Folman RS
Oncology; 1993 Apr; 50 Suppl 1():24-30. PubMed ID: 8387175
[TBL] [Abstract][Full Text] [Related]
20. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
Cavo M; Benni M; Ronconi S; Fiacchini M; Gozzetti A; Zamagni E; Cellini C; Tosi P; Baccarani M; Tura S;
Haematologica; 2002 Sep; 87(9):934-42. PubMed ID: 12217805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
